Radiation safety problems during the patient traveling by public transport after radiopharmaceutical therapy with 131I-Reference-Cited by-同舟云学术

Radiation safety problems during the patient traveling by public transport after radiopharmaceutical therapy with 131I

Published:2024-07-07 Issue:2 Volume:17 Page:97-108
ISSN:2409-9082
Container-title:Radiatsionnaya Gygiena = Radiation Hygiene
language:
Short-container-title:Radiac. gig. (2008)

Author:

Petryakova A. V.¹^ORCID,Chipiga L. A.²^ORCID,Zvonova I. A.³^ORCID,Vodovatov A. V.⁴^ORCID,Gorsky G. A.⁵^ORCID,Stanzhevsky A. A.⁶^ORCID

Affiliation:

1. Saint-Petersburg Research Institute of Radiation Hygiene after Professor P.V. Ramzaev, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing; The City Hospital No 40 of the Kurortny District

2. Saint-Petersburg Research Institute of Radiation Hygiene after Professor P.V. Ramzaev, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing; A.Granov Russian Scientific Center of Radiology and Surgical Technologies of the Ministry of Health of the Russian Federation; Almazov National Medical Research Centre of the Ministry of Health of the Russian Federation

3. Saint-Petersburg Research Institute of Radiation Hygiene after Professor P.V. Ramzaev, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing

4. Saint-Petersburg Research Institute of Radiation Hygiene after Professor P.V. Ramzaev, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing; Saint-Petersburg State Pediatric Medical University

5. Saint-Petersburg Research Institute of Radiation Hygiene after Professor P.V. Ramzaev, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing; I. Mechnikov North Western State Medical University

6. A.Granov Russian Scientific Center of Radiology and Surgical Technologies of the Ministry of Health of the Russian Federation

Abstract

Radiopharmaceutical therapy with 131I has been one of the most common types of radiopharmaceutical therapy for many years. Radiation safety of the public is ensured by limiting the patient contacts until the radiological parameters are reduced to the established criteria. To increase the availability of the radiopharmaceutical therapy with 131I, softer patient release criteria for 131I have been proposed. However, early patient release may increase exposure to the public, e.g. in transport. The aim of the work is to evaluate the radiation exposure from patients with 131I -MIBG and Na131I on the public in transport considering the generation of biological waste. In this work, 131I excretion from the body of patients in transport was evaluated for different scenarios of patient travel to the place of residence. As a result, it was found that mitigation of patient release criteria leads to an increase in the effective dose to the public in transport and an increase in the 131I activity excreted with patient waste. The specific activity in the tanks of biotoilets in transport, generated after the pas -sage of a patient with injected 131I -labeled radiopharmaceuticals, exceeds the limit value of classifying liquid waste as radioactive. To optimize radiation protection of the public, it is advisable to apply a differentiated approach to release patients after therapy with 131I: to group non-resident patients into a separate category retaining for them the established release criterion (without mitigation) to minimize the radiation impact on the public.

Publisher

SPRI of Radiation Hygiene Prof. PV Ramzaev

Reference19 articles.

1. Evaluation of Medical Exposure to Ionizing Radiation. United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR) 2020/2021 Report Volume I. Annex A.

2. Zvonova IA, Likhtarev IA, Nikolaeva AA. Thyroid irradiation accompanying radioiodine examination of patients with thyroid diseases. Meditsinskaya Radiologiya = Medical radiology. 1984;4:42-44. (In Russian).

3. Carrasquillo JA, Chen CC. Neuroendocrine Tumors: Therapy with 131I-MIBG. In: Strauss H, Mariani G, Volterrani D, Larson S. (eds). Nuclear Oncology. Springer: Cham; 2016. P. 1-38. https://doi.org/10.1007/978-3-319-26067-9_26-1.

4. Chipiga LA, Ladanova ER, Vodovatov AV, Zvonova IA, Mosunov AA, Naurzbaeva LT, et al. Trends in the development of nuclear medicine in the Russian Federation for 2015–2020. Radiatsionnaya Gygiena = Radiation Hygiene . 2022;15(4): 122-133. (In Russian) https://doi.org/10.21514/1998-426X-2022-15-4-122-133.

5. Chipiga LA, Zvonova IA, Vodovatov AV, Petryakova AV, Stanzhevsky AA, Vazhenina DA, et al. Improvement of the approach to definition of patient release criteria after radionuclide therapy. Radiatsionnaya Gygiena = Radiation Hygiene. 2023;16(2): 19-31. (In Russian).